Specifically, pre-treatment higher concentrations of blood circulating CD133+ EVs were associated with reduced ORR and shorter PFS in patients with advanced CRC treated with a fluoropyrimidine-based chemotherapy regimen. This evidence concerns the gene PROM1 and colorectal carcinoma.